Form 4: OptimizeRx CEO William Febbo Acquires 20,000 Shares in Open Market Purchase
SEC Form 4 Filing
OptimizeRx CEO William Febbo purchased 20,000 shares of company stock at an average price of $5.011 per share on December 12, 2024.
Summary
- OptimizeRx CEO William Febbo acquired 20,000 shares of common stock on December 12, 2024.
- The shares were purchased at a weighted average price of $5.011, with individual transaction prices ranging from $5.01 to $5.05.
- Following this transaction, Mr. Febbo directly owns 601,253 shares of OptimizeRx stock.
- The filing of this statement does not constitute an admission of beneficial ownership for the purposes of Section 16 of the Securities Exchange Act of 1934.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO's purchase of shares is a positive sign, but it's a routine transaction and doesn't indicate a major shift in the company's outlook.
Positives
- The CEO's purchase of shares could be seen as a positive signal of confidence in the company's future prospects.
- The purchase increases the CEO's stake in the company, aligning his interests with those of other shareholders.
Risks
- There are no specific risks mentioned in this document.
Industry Context
This is a standard SEC Form 4 filing, which is common for corporate insiders who trade their company's stock. It is a routine disclosure and does not necessarily indicate a significant shift in the company's outlook or performance.
Comparison to Industry Standards
- Form 4 filings are a standard practice for publicly traded companies in the United States, and this filing is consistent with those requirements.
- The purchase of shares by a CEO is not uncommon and is often seen as a positive sign, but the impact on the stock price can vary depending on market conditions and other factors.
Stakeholder Impact
- The purchase of shares by the CEO may be viewed positively by shareholders, potentially increasing confidence in the company's leadership and future prospects.
Key Dates
| Date | Description |
|---|---|
| 12/12/2024 | Date of the stock purchase transaction by William Febbo. |
| 12/16/2024 | Date the Form 4 was signed. |
Keywords
OptimizeRx, OPRX, William Febbo, insider trading, stock purchase, CEO, share acquisition, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.